JP2011116755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011116755A5 JP2011116755A5 JP2010253326A JP2010253326A JP2011116755A5 JP 2011116755 A5 JP2011116755 A5 JP 2011116755A5 JP 2010253326 A JP2010253326 A JP 2010253326A JP 2010253326 A JP2010253326 A JP 2010253326A JP 2011116755 A5 JP2011116755 A5 JP 2011116755A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- cancer
- inhibitor
- specifically binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 18
- 229940022399 cancer vaccine Drugs 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 108020004999 messenger RNA Proteins 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45103903P | 2003-02-28 | 2003-02-28 | |
| US60/451,039 | 2003-02-28 | ||
| US48214303P | 2003-06-24 | 2003-06-24 | |
| US60/482,143 | 2003-06-24 | ||
| US53170403P | 2003-12-22 | 2003-12-22 | |
| US60/531,704 | 2003-12-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508934A Division JP2006523226A (ja) | 2003-02-28 | 2004-03-01 | Ｔ細胞調節方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013217056A Division JP2014058523A (ja) | 2003-02-28 | 2013-10-18 | Ｔ細胞調節方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011116755A JP2011116755A (ja) | 2011-06-16 |
| JP2011116755A5 true JP2011116755A5 (enExample) | 2012-02-09 |
Family
ID=32966451
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508934A Withdrawn JP2006523226A (ja) | 2003-02-28 | 2004-03-01 | Ｔ細胞調節方法 |
| JP2010253326A Withdrawn JP2011116755A (ja) | 2003-02-28 | 2010-11-12 | Ｔ細胞調節方法 |
| JP2013217056A Withdrawn JP2014058523A (ja) | 2003-02-28 | 2013-10-18 | Ｔ細胞調節方法 |
| JP2016080113A Withdrawn JP2016169216A (ja) | 2003-02-28 | 2016-04-13 | Ｔ細胞調節方法 |
| JP2017142742A Expired - Lifetime JP6758259B2 (ja) | 2003-02-28 | 2017-07-24 | Ｔ細胞調節方法 |
| JP2019072698A Withdrawn JP2019135247A (ja) | 2003-02-28 | 2019-04-05 | Ｔ細胞調節方法 |
| JP2021214040A Pending JP2022034067A (ja) | 2003-02-28 | 2021-12-28 | Ｔ細胞調節方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508934A Withdrawn JP2006523226A (ja) | 2003-02-28 | 2004-03-01 | Ｔ細胞調節方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013217056A Withdrawn JP2014058523A (ja) | 2003-02-28 | 2013-10-18 | Ｔ細胞調節方法 |
| JP2016080113A Withdrawn JP2016169216A (ja) | 2003-02-28 | 2016-04-13 | Ｔ細胞調節方法 |
| JP2017142742A Expired - Lifetime JP6758259B2 (ja) | 2003-02-28 | 2017-07-24 | Ｔ細胞調節方法 |
| JP2019072698A Withdrawn JP2019135247A (ja) | 2003-02-28 | 2019-04-05 | Ｔ細胞調節方法 |
| JP2021214040A Pending JP2022034067A (ja) | 2003-02-28 | 2021-12-28 | Ｔ細胞調節方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (8) | US20060240024A1 (enExample) |
| EP (4) | EP1897548B2 (enExample) |
| JP (7) | JP2006523226A (enExample) |
| AU (1) | AU2004217526B2 (enExample) |
| CA (1) | CA2517287C (enExample) |
| CY (1) | CY1114755T1 (enExample) |
| DK (1) | DK1897548T4 (enExample) |
| ES (1) | ES2439580T5 (enExample) |
| FI (1) | FI1897548T4 (enExample) |
| PL (1) | PL1897548T5 (enExample) |
| PT (1) | PT1897548E (enExample) |
| SI (1) | SI1897548T2 (enExample) |
| WO (1) | WO2004078928A2 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060240024A1 (en) | 2003-02-28 | 2006-10-26 | The Johns Hopkins University | T cell regulation |
| WO2006044864A2 (en) * | 2004-10-19 | 2006-04-27 | Duke University | Vaccine adjuvant |
| PL1928492T3 (pl) * | 2005-09-01 | 2011-09-30 | Celgene Corp | Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby |
| US20090317407A1 (en) * | 2006-05-02 | 2009-12-24 | Lacelle Michael G | Augmentation of immune response to cancer vaccine |
| WO2008126940A1 (ja) * | 2007-04-10 | 2008-10-23 | The University Of Tokyo | 新規ｔ細胞 |
| EP1987839A1 (en) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US20110059471A1 (en) * | 2008-03-14 | 2011-03-10 | Medinet Co., Ltd. | Antibody having an immune-enhancement function |
| EP2267118A4 (en) * | 2008-03-27 | 2013-08-28 | Takara Bio Inc | METHOD FOR PRODUCING A TRANSFICED CELL |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010062966A2 (en) * | 2008-11-26 | 2010-06-03 | The General Hospital Corporation | Methods for inducing mixed chimerism |
| RU2657440C2 (ru) | 2011-06-30 | 2018-06-13 | Джензим Корпорейшн | Ингибиторы т-клеточной активации |
| WO2013063504A1 (en) * | 2011-10-26 | 2013-05-02 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| JP2016507520A (ja) | 2013-01-23 | 2016-03-10 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 安定化されたｂ型肝炎コアポリペプチド |
| RS60538B1 (sr) | 2013-03-15 | 2020-08-31 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 vezujući proteini |
| ES2935257T3 (es) | 2013-03-15 | 2023-03-03 | Univ Chicago | Métodos y composiciones relacionadas con la actividad de las células T |
| RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| EP3049442A4 (en) * | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| US20170035864A1 (en) * | 2013-12-09 | 2017-02-09 | Bullet Biotechnology, Inc. | SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| US20170165364A1 (en) * | 2014-02-21 | 2017-06-15 | Idac Theranostics, Inc. | Therapeutic agent for solid cancer |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| LT3148579T (lt) | 2014-05-28 | 2021-05-25 | Agenus Inc. | Anti-gitr antikūnai ir jų panaudojimo būdai |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| CA2964155A1 (en) | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| MA41463A (fr) * | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| TWI702290B (zh) * | 2015-04-07 | 2020-08-21 | 富禾生醫股份有限公司 | 經修飾之自然殺手ｔ細胞、醫藥組合物及其用途 |
| EA039293B1 (ru) * | 2015-06-05 | 2021-12-30 | Мерк Шарп И Доум Корп. | Антитела против lag3 и антигенсвязывающие фрагменты |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| WO2017004252A1 (en) | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
| US12577289B2 (en) | 2015-06-30 | 2026-03-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Surrogate co-receptors for t cells and methods of use |
| MX2018000447A (es) | 2015-07-15 | 2018-08-15 | Pieris Pharmaceuticals Gmbh | Novedosas proteinas especificas para lag-3. |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| AU2016303497A1 (en) * | 2015-07-31 | 2018-03-01 | Tarveda Therapeutics, Inc. | Compositions and methods for immuno-oncology therapies |
| RU2760582C2 (ru) | 2015-09-02 | 2021-11-29 | Иммутеп С.А.С. | Анти-LAG-3 антитела |
| MA43028B1 (fr) | 2015-10-02 | 2021-09-30 | Hoffmann La Roche | Anticorps bispécifiques pour pd1 et tim3 |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| CN108366548B (zh) | 2015-11-20 | 2021-10-08 | 瑞泽恩制药公司 | 具有人源化淋巴细胞活化基因3的非人动物 |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| BR112018012352A2 (pt) | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-lag3 e fragmentos de ligação ao antígeno |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| BR112018068461A2 (pt) | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US11155617B2 (en) | 2016-06-23 | 2021-10-26 | Jiangsu Hengrui Medicine Co., Ltd. | LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
| EA039718B1 (ru) * | 2016-07-21 | 2022-03-03 | Регенерон Фармасьютикалз, Инк. | Антитела к lag3 и их применения |
| MY190805A (en) * | 2016-09-08 | 2022-05-12 | Daiichi Sankyo Co Ltd | Antibody for treating autoimmune diseases |
| KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| CN108070613B (zh) | 2016-11-11 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018086583A1 (en) * | 2016-11-11 | 2018-05-17 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric lag-3 |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| JP7225116B2 (ja) | 2017-01-18 | 2023-02-20 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| TW201834697A (zh) | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Her2標靶抗體－藥物結合物之組合療法 |
| KR102461885B1 (ko) | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| UA128387C2 (uk) | 2017-04-05 | 2024-07-03 | Ф. Хоффманн-Ля Рош Аг | Антитіло до lag3 |
| CA3052532A1 (en) | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Bispecific antibodies specifically binding to pd1 and lag3 |
| JP7301002B2 (ja) | 2017-05-30 | 2023-06-30 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物 |
| WO2018222718A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
| AU2018283319B2 (en) * | 2017-06-16 | 2023-11-09 | Mayo Foundation For Medical Education And Research | Materials and methods for increasing immune responses |
| JP6896989B2 (ja) * | 2017-07-13 | 2021-06-30 | ナンジン リーズ バイオラブズ カンパニー リミテッド | 抗体結合ｌａｇ−３及びその使用 |
| US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| CN111757757A (zh) | 2017-12-21 | 2020-10-09 | 梅尔莎纳医疗公司 | 吡咯并苯并二氮呯抗体共轭物 |
| EP3714901A4 (en) * | 2017-12-22 | 2022-03-02 | Jiangsu Hengrui Medicine Co., Ltd. | ANTI-LAG-3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| WO2019133847A1 (en) | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
| JP2021511793A (ja) | 2018-01-31 | 2021-05-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体 |
| CA3117050A1 (en) | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| WO2020125763A1 (en) | 2018-12-20 | 2020-06-25 | Biocytogen Jiangsu Co., Ltd. | Genetically modified non-human animal with human or chimeric lag3 |
| CN109666699B (zh) * | 2018-12-29 | 2023-02-28 | 杭州科兴生物科技有限公司 | 一种基于lag-3/mhc ii阻断功能及其生物效应的药物快速筛选方法 |
| US20220214333A1 (en) * | 2019-04-16 | 2022-07-07 | Regents Of The University Of Minnesota | Biomarker for transplantation tolerance induced by apoptotic donor leukocytes |
| CA3136568A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| CN111415707B (zh) * | 2020-03-10 | 2023-04-25 | 四川大学 | 临床个体化肿瘤新抗原的预测方法 |
| CN111808192B (zh) * | 2020-06-05 | 2022-02-15 | 北京天广实生物技术股份有限公司 | 结合lag3的抗体及其用途 |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| JP2022176672A (ja) * | 2021-05-17 | 2022-11-30 | 国立大学法人北海道大学 | ペプチド及び医薬用組成物 |
| WO2022245816A1 (en) * | 2021-05-18 | 2022-11-24 | Pelican Therapeutics, Inc. | Treatment of autoimmune inflammatory diseases with tnfrsf25-binding agents |
| CN121127264A (zh) | 2023-03-13 | 2025-12-12 | 瑞泽恩制药公司 | 用于在治疗黑素瘤中增强疗效的pd-1抑制剂和lag-3抑制剂组合 |
| CN122180519A (zh) | 2023-11-15 | 2026-06-09 | 瑞泽恩制药公司 | 用于增强在治疗肺癌中的功效的pd-1抑制剂和lag-3抑制剂的组合 |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
| US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
| US4658957A (en) * | 1985-01-28 | 1987-04-21 | Abbott Laboratories | Utility tray |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| FR2656800B1 (fr) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5976877A (en) * | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
| JP3700859B2 (ja) | 1994-05-06 | 2005-09-28 | アンスティテュ ギュスタブ ルシ | Ｌａｇ−３タンパク質の可溶性ポリペプチドフラクション；製造方法、治療用製剤、抗イディオタイプ抗体 |
| PT843557E (pt) * | 1995-07-21 | 2003-03-31 | Applied Research Systems | Metodos para detectar indentificar isolar e etiquetar e abordar selectivamente linfocitos th1 por intermedio da proteina lag-3 |
| WO1997032970A1 (en) | 1996-03-04 | 1997-09-12 | Targeted Genetics Corporation | Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes |
| DE69739951D1 (de) * | 1996-03-04 | 2010-09-16 | Calyx Bio Ventures Inc | Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten |
| US6482925B1 (en) * | 1996-11-28 | 2002-11-19 | Applied Research Systems Ars Holding N.V. | Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants |
| DE69632967T2 (de) * | 1996-11-29 | 2005-08-11 | Applied Research Systems Ars Holding N.V. | Verfahren zur Verhinderung der Transplantabstoßung bei einer Transplantation und zur Herstellung einer universalen Gentherapie-Wirtszelle unter Anwendung von Lymphocyten-Aktivierungsgen (LAG-3) |
| CN1196786C (zh) * | 1996-11-29 | 2005-04-13 | 应用研究系统Ars股份公司 | 抗移植排斥细胞及其用途 |
| EP0900841A1 (en) * | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
| EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
| JPH1164707A (ja) * | 1997-08-13 | 1999-03-05 | Fuji Photo Optical Co Ltd | ズームレンズ鏡筒 |
| US6432925B1 (en) * | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
| GB0007088D0 (en) * | 2000-03-23 | 2000-05-17 | Torsana A S | Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates |
| EP1539805A4 (en) | 2001-05-15 | 2005-11-16 | Agensys Inc | NUCLEIC ACIDS SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER AND CORRESPONDING PROTEINS NAMED 101P3A11 OR PHOR-1 |
| JP2005500025A (ja) * | 2001-05-29 | 2005-01-06 | サーナ・セラピューティクス・インコーポレイテッド | 女性生殖疾病及び状態の核酸に基づく調節 |
| ES2305257T3 (es) * | 2001-06-12 | 2008-11-01 | Bayer Cropscience Ag | Plantas transgenicas que sintetizan almidon rico en amilosa. |
| WO2003010180A1 (en) * | 2001-07-23 | 2003-02-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for rnai mediated inhibition of gene expression in mammals |
| US20060240024A1 (en) | 2003-02-28 | 2006-10-26 | The Johns Hopkins University | T cell regulation |
| MXPA05014155A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
| TWI468417B (zh) * | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
-
2004
- 2004-03-01 US US10/547,371 patent/US20060240024A1/en not_active Abandoned
- 2004-03-01 EP EP07021595.9A patent/EP1897548B2/en not_active Expired - Lifetime
- 2004-03-01 AU AU2004217526A patent/AU2004217526B2/en not_active Expired
- 2004-03-01 EP EP18177034.8A patent/EP3427741A3/en not_active Withdrawn
- 2004-03-01 CA CA2517287A patent/CA2517287C/en not_active Expired - Lifetime
- 2004-03-01 PT PT70215959T patent/PT1897548E/pt unknown
- 2004-03-01 ES ES07021595T patent/ES2439580T5/es not_active Expired - Lifetime
- 2004-03-01 DK DK07021595.9T patent/DK1897548T4/da active
- 2004-03-01 FI FIEP07021595.9T patent/FI1897548T4/fi active
- 2004-03-01 EP EP04716126A patent/EP1596871A4/en not_active Withdrawn
- 2004-03-01 SI SI200432110T patent/SI1897548T2/sl unknown
- 2004-03-01 JP JP2006508934A patent/JP2006523226A/ja not_active Withdrawn
- 2004-03-01 PL PL07021595.9T patent/PL1897548T5/pl unknown
- 2004-03-01 EP EP20130179162 patent/EP2659893A3/en not_active Withdrawn
- 2004-03-01 WO PCT/US2004/006133 patent/WO2004078928A2/en not_active Ceased
-
2009
- 2009-10-22 US US12/578,887 patent/US8551481B2/en not_active Expired - Fee Related
-
2010
- 2010-11-12 JP JP2010253326A patent/JP2011116755A/ja not_active Withdrawn
-
2012
- 2012-11-16 US US13/679,485 patent/US9005629B2/en not_active Expired - Lifetime
-
2013
- 2013-10-18 JP JP2013217056A patent/JP2014058523A/ja not_active Withdrawn
- 2013-11-14 CY CY20131101011T patent/CY1114755T1/el unknown
- 2013-12-13 US US14/105,293 patent/US20140127226A1/en not_active Abandoned
-
2015
- 2015-12-18 US US14/973,806 patent/US10787513B2/en active Active
-
2016
- 2016-04-13 JP JP2016080113A patent/JP2016169216A/ja not_active Withdrawn
-
2017
- 2017-07-24 JP JP2017142742A patent/JP6758259B2/ja not_active Expired - Lifetime
-
2018
- 2018-03-30 US US15/942,168 patent/US10934354B2/en not_active Expired - Fee Related
-
2019
- 2019-04-05 JP JP2019072698A patent/JP2019135247A/ja not_active Withdrawn
-
2021
- 2021-01-22 US US17/155,228 patent/US20210230275A1/en not_active Abandoned
- 2021-12-28 JP JP2021214040A patent/JP2022034067A/ja active Pending
-
2023
- 2023-06-06 US US18/206,552 patent/US20240174747A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schinkel et al. | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview | |
| Jung et al. | The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo | |
| ZA202106265B (en) | Compositions and methods for inhibiting gene expression of lpa | |
| WO2014022739A3 (en) | Modified rnai agents | |
| JP7266534B2 (ja) | 天然化合物および線維症 | |
| MX373926B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| JP2011251975A5 (enExample) | ||
| CL2014003637A1 (es) | Anticuerpo monoclonal optimizado que se une al gen 3 de activación de linfocitos (lag-3); molécula biespecífica que lo comprende; inmunoconjugado que comprende el anticuerpo unido a un agente terapéutico; composición; ácido nucleico; vector; célula huésped; método de preparación; y uso para inhibir el crecimiento de un tumor o tratar una infección viral. | |
| EA201290712A1 (ru) | Альфа-излучающие комплексы | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| UA115517C2 (uk) | Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| UA117072C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським | |
| WO2012135671A3 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| Bahreyni et al. | Synergistic viro-chemoimmunotherapy in breast cancer enabled by bioengineered immunostimulatory exosomes and dual-targeted coxsackievirus B3 | |
| JP2014523398A5 (enExample) | ||
| BR112013002738A2 (pt) | métodos e compostos para o diagnóstico e o tratamento do câncer | |
| BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
| Kim et al. | A small molecule, 4-phenylbutyric acid, suppresses HCV replication via epigenetically induced hepatic hepcidin | |
| Liu et al. | ShRNA-mediated silencing of the Ndc80 gene suppress cell proliferation and affected hepatitis B virus-related hepatocellular carcinoma | |
| Xiao et al. | Inhibition of microRNA-429 attenuates oxygen–glucose deprivation/reoxygenation-induced neuronal injury by promoting expression of GATA-binding protein 4 | |
| Tang et al. | Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy | |
| RU2015139515A (ru) | Комбинированное лечение | |
| JP2011500650A5 (enExample) | ||
| BR112013025410A2 (pt) | tratamento terapêutico |